| NCT01561963 | phase1 | completed | 2012-02-01 | 2012-04-01 | Amgen | A Drug-Drug Interaction Study to Evaluate the Effect of Rifampin on the Pharmacokinetics of Apremilast |
| NCT04175613 | phase3 | completed | 2019-12-20 | 2025-10-30 | Amgen | A Long-term Extension Study of Apremilast (CC-10004) in Pediatric Subjects From 6 Through 17 Years of Age With Moderate to Severe Plaque Psoriasis |
| NCT02307513 | phase3 | completed | 2014-12-30 | 2017-09-25 | Amgen | A Phase 3 Randomized, Double-blind Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in Subjects With Active Behçet's Disease |
| NCT03930186 | phase3 | completed | 2019-06-17 | 2020-05-08 | Amgen | A Phase 3B, Open-label, Single-arm Study of the Efficacy and Safety of Apremilast, in Subjects With Plaque Psoriasis That is Not Adequately Controlled by Topical Therapy |
| NCT02425826 | phase4 | completed | 2015-04-20 | 2016-02-12 | Amgen | A Phase 4 Study of Efficacy and Safety of Apremilast in Subjects With Moderate Plaque Psoriasis. |